Mitochondrial-derived peptide ('exercise mimetic')
A 16-amino-acid peptide encoded in mitochondrial DNA that acts as a metabolic signaling molecule.
| Class / type | Mitochondrial-derived peptide ('exercise mimetic') |
|---|---|
| Category | Longevity & Cellular |
| Status (Jul 2026) | Research use only |
MOTS-c is a small peptide encoded within mitochondrial DNA that acts as a metabolic signaling molecule. Interest centers on its role as a natural 'exercise signal' - blood levels rise with physical activity - and on animal data suggesting it improves metabolism.
Human clinical trials are essentially absent, so its marketing (energy, fat loss, endurance) runs well ahead of the proof. It is sold research-use-only.
MOTS-c activates AMPK, the enzyme that governs cellular energy balance, largely through the folate-AICAR pathway. This increases muscle glucose uptake and fat oxidation, and under metabolic stress MOTS-c can move into the nucleus to influence gene expression.
Preclinical (cell and rodent) studies show improved insulin sensitivity, endurance and glucose handling, and human observational work shows circulating MOTS-c rises with exercise. But direct human efficacy trials are lacking, so benefits in people are extrapolated rather than demonstrated.
A compelling 'exercise-in-a-vial' rationale, with preclinical support for metabolic and endurance effects.
Users report increased energy and exercise capacity, though this is anecdotal.
Human safety data are minimal because clinical trials are essentially absent. Injection-site reactions are possible, and gray-market purity is a concern.
The gap between marketing claims and actual human evidence is large - a key thing for readers to weigh.
Sold research-use-only. In July 2026 an FDA advisory panel voted to recommend it for compounding, but that vote is advisory and not yet final. No FDA-sanctioned human dose exists.
'Exercise in a vial' - perceived energy, endurance and fat-loss support with training.
NOT FDA-approved; research-use-only. On Jul 23, 2026 the FDA's PCAC voted to recommend it for 503A compounding (advisory only); no final rule yet. The next step is formal FDA rulemaking with a public comment period, and the FDA may allow interim enforcement discretion in the meantime. Verify.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.